KRAS mutant lung cancer: progress thus far on an elusive therapeutic target. Issue 1 (14th December 2015)

• Record Type: Journal Article
• Authors: Bhattacharya, Saveri; Socinski, Mark A.; Burns, Timothy F.
• Is Part Of: Clinical and translational medicine. Volume 4:Issue 1(2015)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2015-12-14
• Subjects: KRAS mutant NSCLC -- MAPK pathway -- Targeted therapy; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1186/s40169-015-0075-0
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: The KRAS mutation remains the most common driver mutation in patients with non‐small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS‐RAF‐MEK‐ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.